Monovalent A/H1N1 influenza vaccine

BIOLOGICAL5 trials

Sponsors

Novartis Vaccines

Conditions

Pandemic InfluenzaPandemic Influenza Disease

Phase 2

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

CompletedNCT00992212

Novartis VaccinesPandemic Influenza Disease

Start: 2009-08-31End: 2009-11-30Updated: 2016-12-01

Phase 3

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

CompletedNCT00970177

Novartis VaccinesPandemic Influenza

Start: 2009-08-31End: 2011-03-31Updated: 2016-12-01

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

CompletedNCT00971542

Novartis VaccinesPandemic Influenza

Start: 2009-09-30End: 2011-07-31Updated: 2011-10-12

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

CompletedNCT00971100

Novartis VaccinesPandemic Influenza

Start: 2009-08-31End: 2011-08-31Updated: 2016-12-01

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

CompletedNCT00971906

Novartis VaccinesPandemic Influenza

Start: 2009-08-31End: 2011-04-30Updated: 2020-02-11

Related Papers

A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.

2012-03-2222 citations